KEYLYNK-013: A phase 3 study of pembrolizumab in combination with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy in patients with newly diagnosed limited-stage SCLC.

Andreas Rimner,W. Victoria Victoria Lai,Raffaele Califano,Salma K. Jabbour,Corinne Faivre-Finn,Byoung Chul Cho,Terufumi Kato,Jinming Yu,Li Yu,Bin Zhao,M.C. Pietanza,Lauren Averett Byers

KEYLYNK-013: A phase 3 study of pembrolizumab in combination with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy in patients with newly diagnosed limited-stage SCLC.

2021

Andreas Rimner
W. Victoria Victoria Lai
Raffaele Califano
Salma K. Jabbour
Corinne Faivre-Finn
Byoung Chul Cho
Terufumi Kato
Jinming Yu
Li Yu
Bin Zhao
M.C. Pietanza
Lauren Averett Byers

TPS8587Background: Concurrent chemoradiotherapy with etoposide and platinum (carboplatin/cisplatin) plus the anti‒PD-1 antibody pembrolizumab (pembro) has shown antitumor activity and acceptable sa...

Keywords:

Internal medicine
Etoposide
Medicine
Phases of clinical research
Pembrolizumab
concurrent chemoradiation
Oncology
Olaparib
in patient
Cisplatin
Carboplatin

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations